Geoffrey Cumming
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Geoffrey Cumming
Non-Executive Director / Anteo Diagnostics
Geoffrey Cumming has over 20 years of experience in senior roles within the global healthcare and biotechnology sector.
As managing director of Roche Diagnostic Systems (Oceania), Mr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. As managing director and chief executive of Biosceptre International, he designed and secured key funding arrangements through a range of capital raising initiatives including large government grants, partnering and co-development deals. Mr Cumming was also managing director and chief executive of Anteo Diagnostics, chair of Sienna Cancer Diagnostics, and non-executive director of ASX-listed Medical Australia.
As managing director of Roche Diagnostic Systems (Oceania), Mr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. As managing director and chief executive of Biosceptre International, he designed and secured key funding arrangements through a range of capital raising initiatives including large government grants, partnering and co-development deals. Mr Cumming was also managing director and chief executive of Anteo Diagnostics, chair of Sienna Cancer Diagnostics, and non-executive director of ASX-listed Medical Australia.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 291st | INOVIQ | 33% | 109% |
| 703rd | Frugl Group | 0% | -20% |
| 766th | Advanced Health Intelligence | -2% | -24% |
| 1615th | Nanollose | -60% | -21% |
| 1865th | Invex Therapeutics | -83% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 157th |  | INOVIQ | $1.6m |
| 172nd | | Frugl Group | $806k |
| 173rd | | Advanced Health Intelligence | $772k |
| 175th |  | Invex Therapeutics | $459k |
| 176th |  | Nanollose | $412k |
201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEWS: Tagged in Board Moves October 11, 2023 | 11 Oct 2023 |
| NEWS: Tagged in Leaders meet to discuss isolation changes | 31 Aug 2022 |
| NEW ROLE: Managing Director, Chief Executive, Anteo Diagnostics | 03 Aug 2020 |
| NEW ROLE: Non-Executive Chair, Sienna Cancer Diagnostics | 03 Aug 2020 |
| NEW ROLE: Non-Executive Director, Anteo Diagnostics | 03 Aug 2020 |
| NEW ROLE: Non-Executive Director, was Chair 2020-2023, INOVIQ | 03 Aug 2020 |
